We have investigated the presence of a cAMP-protein kinase A-dependent pathway in cerebrocortical nerve terminals and its role in the modulation of glutamate release. The activation of adenylyl cyclase with forskolin enhances intrasynaptosomal cAMP and induces Ca 2؉ -dependent glutamate release. The membrane permeant analogue dibutyryl cAMP mimics this facilitatory effect, whereas the inactive compound 1,9-dideoxyforskolin is without effect. This cAMP-induced facilitation is consistent with the induction of spontaneous action potentials that are abolished by the Na ؉ channel blocker tetrodotoxin and by reducing nerve terminal excitability with arachidonic acid. We have also demonstrated that a ␤-adrenergic receptor is linked to this pathway because isoproterenol increases cAMP levels and glutamate release, and both actions are antagonized by the receptor antagonist propanolol and the protein kinase A inhibitors H89 and 8-chloroadenosine 3,5-monophosphorothioate ((R p )-isomer). The finding that the increase in cytoplasmic free Ca 2؉ concentration induced by synaptic activity reduces the concentration of agonist required to maximally activate adenylyl cyclase suggests that this enzyme may act as a coincidence detector, integrating glutamatergic neurotransmission and noradrenaline release.
In the central nervous system, adenylyl cyclases regulate many cellular processes in response to extracellular and intracellular signals such as hormones, neurotransmitters, and Ca 2ϩ (1) . Inmunohistochemical studies of adenylyl cyclase in the brain have shown a selective concentration at synapses both in presynaptic axon terminals and in postsynaptic densities (2) . Consistent with this localization, the activation of adenylyl cyclase with forskolin has been shown to enhance synaptic transmission in hippocampal slices from CA1 (3, 4) , CA3 (5, 6) , and the dentate gyrus (7) as well as in neostriatal neurons (8) . Moreover, the cAMP-dependent effects on synaptic transmission have been implicated in long-term potentiation in the hippocampus both in CA1 neurons (9) and in slices from the CA3 region (6, 10) . Recently, evidence has been found indicating that the extracellular signal involved in the activation of this cAMP-dependent pathway is noradrenaline, acting via a ␤-adrenergic receptor. Thus, the ␤-adrenergic agonist isoproterenol has been shown to mimic the potentiating effects of cAMP elevation in synaptic transmission (11, 12) .
Although it has been suggested that an increase in glutamate release at the axon terminal is responsible for the ␤-adrenergic receptor/cAMP-mediated potentiation of transmission (4, 10 -12) , the mechanism of this facilitation has not been established. Moreover, the fact that PKA, 1 acting at the postsynaptic level, has been shown to enhance both N-methyl-D-aspartic acid-mediated (13) and (R, S)-␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid/kainate-mediated (14 -16) responses means that it is not possible to rule out a postsynaptic contribution of the cAMP-dependent pathway to synaptic potentiation. For these reasons, we addressed whether a ␤-adrenergic receptor/cAMP/PKA-dependent pathway facilitates the release of glutamate. In addition, we have also studied the mechanism involved in this facilitation.
The preparation of nerve terminals from the cerebral cortex has proved to be a good model to demonstrate the presence of a protein kinase C-dependent facilitatory pathway governed by a metabotropic glutamate receptor (17) . In this paper, we provide direct evidence for the presence of a ␤-adrenergic receptor/ cAMP/PKA facilitatory pathway in nerve terminals from the cerebral cortex. The cAMP-mediated facilitation is consistent with the induction of spontaneous action potentials that lead to Ca 2ϩ -dependent glutamate release. This increase in spontaneous activity by cAMP is prevented by the Na ϩ channel blocker tetrodotoxin or by reduction of the nerve terminal excitability with arachidonic acid. We have also demonstrated that a ␤-adrenergic receptor is linked to this pathway, given that the agonist isoproterenol facilitates glutamate release, while the ␤-adrenergic antagonist propanolol prevents this effect. Finally, the dependence of this facilitatory pathway on the increase in [Ca 2ϩ ] c provided by synaptic activity indicates that an integration of glutamatergic neurotransmission and adrenaline release may occur at the presynaptic level.
EXPERIMENTAL PROCEDURES
Synaptosomal Preparation-Cerebral cortices from Wistar rats (2-3 months) were isolated and homogenized in medium containing 320 mM sucrose, 0.5 mM EDTA, and 5 mM TES, pH 7.4. The homogenate was spun for 5 min at 900 ϫ g at 4°C, and the supernatants were spun again for 10 min at 17,000 ϫ g. From the pellets thus formed, the white loosely compacted layer containing the majority of synaptosomes was gently resuspended in medium containing 250 mM sucrose and 5 mM TES, pH 7.4 (10 ml/four cortices), and protein content was determined by the biuret method. Pellets containing 1 mg of protein were stored on ice. Synaptosomes remained fully viable when stored as pellets for at least 6 h after preparation as judged by the extent of KCl-and 4AP-evoked glutamate release.
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‡ To whom correspondence should be addressed. Tel.: 34-1-394-38-91; Fax: 34-1-394-39-09; E-mail:jsprieto@eucmax.sim.ucm.es. methylxanthine (IBMX) were added, and incubation was continued for another 10 min. Then, forskolin or the pharmacological agonists were added, and samples were taken 10 or 2 min after, respectively. Aliquots (0.5 ml) were added to 0.15 ml of an ice-cold solution containing 1 M HClO 4 and 50 mM EDTA. The samples were shaken and placed in ice for 20 min. Then, the samples were centrifuged at 12,000 ϫ g for 1 min in a bench microcentrifuge. The supernatants were neutralized with a solution of 3 M KOH and 1.5 M triethanolamine. The supernatants were collected, and the cAMP content was estimated by radioimmunoassay with a commercially available cAMP kit from Amersham International (Buckinghamshire, United Kingdom).
Glutamate Release-Glutamate release was assayed by on-line fluorometry as described previously (18) . Synaptosomal pellets were resuspended (0.67 mg/ml) in incubation medium containing 122 mM NaCl, 3.1 mM KCl, 0.4 mM KH 2 PO 4 , 5 mM NaHCO 3 , 1.2 mM MgSO 4 , 10 mM glucose, and 20 mM TES, pH 7.4, and preincubated at 37°C in the presence of 16 M BSA to bind any free fatty acids released from synaptosomes during the preincubation (19) . After a 50-min incubation, adenosine deaminase (1 unit/mg of protein) and 1 mM IBMX were added, and incubation was continued for another 10 min. An aliquot (1 ml) was transferred to a stirred cuvette containing 1 mM NADP ] c was measured with fura-2. Synaptosomes were resuspended (2 mg/ml) in incubation medium containing 16 M BSA in the presence of 1.33 mM CaCl 2 and 5 M fura-2/acetoxymethyl ester and incubated at 37°C for 20 min. Then, adenosine deaminase (1 unit/mg) and 1 mM IBMX were added, and incubation was continued for another 10 min. After fura-2 loading, synaptosomes were pelleted and resuspended in fresh incubation medium containing BSA. An aliquot (1 ml) was transferred to a stirred cuvette containing 1.33 mM CaCl 2 , and the fluorescence was monitored at 340 and 510 nm. Data points were collected at 0.5-s intervals. [Ca 2ϩ ] c was calculated using the equations described by Grynkiewicz et al. (20) .
Plasma Membrane Potential-The plasma membrane potential was estimated with 3,3Ј-diethylthiadicarbocyanine iodide (21) . Synaptosomes in incubation medium (1 mg/ml) containing 16 M BSA were preincubated at 37°C for 50 min. Then, adenosine deaminase (1 unit/ mg) and 1 mM IBMX were added, and incubation was continued for another 10 min. After this time, a 1-ml aliquot was transferred to a stirred cuvette containing 5 M 3,3Ј-diethylthiadicarbocyanine iodide and 1.33 mM CaCl 2 . After 1 min to allow for equilibration, the fluorescence was determined at 643 and 680 nm. Data points were collected at 1-s intervals.
Materials-Forskolin, 1,9-dideoxyforskolin, and H89 were from Calbiochem. (R p )-8-Cl-cAMP-S was from Biolog (Bremen, Germany). 3,3Ј-Diethylthiadicarbocyanine iodide and fura-2/acetoxymethyl ester were from Molecular Probes, Inc. (Eugene, OR). Adenosine deaminase was purchased from Boehringer (Mannheim, Germany). Glutamate dehydrogenase, NADP ϩ , arachidonic acid, isoproterenol, tetrodotoxin, propanolol, dibutyryl cAMP (Bt 2 cAMP), and all other drugs were purchased from Sigma.
RESULTS
cAMP Levels in Nerve Terminals-Basal cAMP levels in cerebrocortical nerve terminals were determined in the presence of 1.33 mM CaCl 2 and adenosine deaminase to prevent tonic activation of the adenosine receptor (22) . Under these conditions, cAMP levels were 11.95 Ϯ 4.31 pmol/mg of protein (mean Ϯ S.D., n ϭ 3; 100 Ϯ 36%). cAMP levels were not significantly altered (104 Ϯ 17%, n ϭ 5) in the presence of the phosphodiesterase inhibitor IBMX at 1 mM (23) . The activation of adenylate cyclase with forskolin (24) at 100 M slightly increased the cAMP concentration in the absence of IBMX (169 Ϯ 28%, n ϭ 5), but strongly enhanced cAMP in the presence of IBMX (1180 Ϯ 45%, n ϭ 5) (Fig. 1A) . The reduction of Ca 2ϩ in the incubation medium from 1.33 mM CaCl 2 to 200 nM free Ca 2ϩ greatly decreased the IBMX/forskolin-stimulated cAMP levels (105 Ϯ 37%, n ϭ 2). These results indicate first, the presence of an active phosphodiesterase for cAMP in cerebrocortical nerve terminals, and second, that presynaptic adenylyl cyclase is a Ca 2ϩ -dependent enzyme (1) . Maximal stimulation of adenylyl cyclase was observed at 100 M forskolin, whereas the inactive analogue 1,9-dideoxyforskolin at 100 M failed to increase the cAMP concentration (Fig. 1B) .
cAMP Levels and Release of Glutamate-In cerebrocortical nerve terminals maintained under polarized conditions (3 mM KCl), no change in the Ca 2ϩ -dependent release was observed over a period of several minutes ( Fig. 2A, Control) , indicating that spontaneous release of glutamate, if it occurs, is too insignificant to be detected by the enzymatic glutamate trap. However, the depolarization of nerve terminals with the K ϩ channel inhibitor 4AP evoked a Ca 2ϩ -dependent glutamate release of 3.05 Ϯ 0.23 nmol of glutamate/mg of protein (mean Ϯ S.D., n ϭ 6) measured over a 5-min period. The ability of 4AP to initiate spontaneous action potentials in nerve terminals has been previously demonstrated (25) . The addition of 100 M forskolin to polarized synaptosomes induced (after a lag of several tens of seconds) an increase in the release of glutamate, which originates from the same Ca 2ϩ -dependent pool of glutamate mobilized by depolarization with 4AP as deduced by the reduction in the release observed by a subsequent addition of 4AP ( Fig. 2A,  Forsk) . The facilitatory effect of forskolin on spontaneous release was prevented by the addition of the Na ϩ channel blocker tetrodotoxin (TTX) (Fig. 2A , TTX ϩ Forsk), suggesting the involvement of action potentials in the forskolin action. TTX also prevented the ability of a subsequent depolarization with 4AP to evoke the Ca 2ϩ -dependent release ( Fig. 2A , TTX ϩ Forsk).
In parallel experiments similar to those shown in Fig. 2A , it was observed that the membrane permeant cAMP analogue Bt 2 cAMP, at 1 mM, mimicked the facilitatory effect of forskolin (Fig. 2B) . It can also be seen that facilitation by forskolin and Bt 2 cAMP was prevented by preincubation of nerve terminals with the blocker of the catalytic site of PKA, H89 (26) , while the inactive analogue 1,9-dideoxyforskolin (100 M) was without effect. This rules out the possibility of forskolin having an effect on glutamate release, independent of cAMP, and suggests the involvement of a PKA-dependent pathway in the facilitation of glutamate release.
Arachidonic acid at micromolar concentrations has been reported to inhibit the synaptic transmission (27) and release (28) of glutamate due to the ability of this fatty acid to decrease nerve terminal excitability by inhibition of Na ϩ channels (29) . We had previously established that presynaptic inhibition by arachidonic acid is only observed under conditions where action potentials are induced by 4AP (28) . For these reasons, we tested whether arachidonic acid was able to antagonize the increase in nerve terminal excitability induced by cAMP. Since arachidonic acid reduced the 4AP-but not KCl-evoked glutamate release (28) , in these experiments, the remaining Ca 2ϩ -dependent release of glutamate after arachidonic acid action was determined with 30 mM KCl. Fig. 3 shows that the membrane permeant cAMP analogue Bt 2 cAMP at 1 mM induced an increase in the spontaneous release of glutamate that diminished the subsequent depolarization evoked by 30 mM KCl (trace b compared with trace a). Arachidonic acid did not alter the spontaneous or the KCl-evoked glutamate release (Fig. 3 , trace c), but was able to prevent the facilitatory effect of dibutyryl cAMP and to restore the release evoked by a subsequent depolarization with 30 mM KCl (Fig. 3, trace d) . These results indicate that the increase in nerve terminal excitability induced by the cAMP analogue is prevented by arachidonic acid.
We have also studied the effects of forskolin on the depolarization-evoked release of glutamate. The stimulation of nerve terminals with a submaximal concentration (50 M) of 4AP evoked a Ca 2ϩ -dependent release of 1.40 Ϯ 0.07 nmol of glutamate/mg of protein (mean Ϯ S.D., n ϭ 5), i.e. 46 Ϯ 2% of that evoked by maximal depolarization with 1 mM 4AP (Fig. 4A) . However, the prior addition of 100 M forskolin potentiates the release evoked by 50 M 4AP to values similar to those obtained with maximal depolarization (Fig. 4A) . Forskolin failed to enhance the release evoked by 1 mM 4AP (data not shown). Thus, these results suggest that the spontaneous action potentials induced by forskolin together with the action potentials evoked by a submaximal concentration of 4AP maximally stimulate the population of nerve terminals to release glutamate. The facilitation of 4AP-evoked glutamate release by forskolin was also mimicked by the cAMP analogue dibutyryl cAMP at 1 mM (Fig. 4B) . We can also see in Fig. 4B how the facilitation induced by both forskolin and Bt 2 cAMP was prevented by the protein kinase A inhibitor H89. Finally, the forskolin-induced potentiation was prevented by the PKA antagonist (R p )-8-ClcAMP-S (Fig. 4B) .
It has been shown previously that the stimulation of nerve terminals with a high concentration of KCl does not involve the induction of action potentials because the Na ϩ channel blocker tetrodotoxin does not prevent KCl-evoked release (25) . Consistent with the involvement of action potentials in forskolin-induced release, this compound did not alter the release of glutamate evoked by a submaximal concentration (10 mM) of KCl (Fig. 4C) .
Mechanism of cAMP-induced Facilitation of Glutamate Release-Submaximal stimulation with 50 M 4AP in the presence of forskolin releases glutamate to a similar extent as that evoked by 1 mM 4AP (Fig. 4A) , suggesting that the effect of forskolin on release is additive to 4AP action. Thus, to understand the mechanism of forskolin-induced facilitation, we de- ] c caused by 50 M 4AP in the presence of forskolin was much lower than that evoked by 1 mM 4AP (Fig. 5A) . Since the extent of glutamate release evoked under both conditions is similar, it is likely that forskolin, in addition to inducing spontaneous action potentials, enhances the sensitivity to Ca 2ϩ of the exocytotic apparatus. In parallel experiments (not shown here), however, we have tested that forskolin does not alter the Ca 2ϩ -dependent release evoked by the Ca 2ϩ ionophore ionomycin, thus ruling out a change in the sensitivity to Ca 2ϩ of the exocytotic machinery. Another alternative explanation for the discrepancy between the release (Fig. 4A ) and the fura-2 experiments (Fig. 5A ) in the presence of forskolin is that the increase in [Ca 2ϩ ] c evoked by 1 mM 4AP is in excess of that required to maximally stimulate the release. It is therefore possible that the action potentials evoked by 4AP are larger than those induced by forskolin. To test for this possibility, we determined the average depolarization of the population of nerve terminals with 3,3Ј-diethylthiadicarbocyanine iodide. We can see in Fig. 5C that 50 M 4AP in the presence of forskolin depolarizes the population of nerve terminals to a lesser extent than 1 mM 4AP. This indicates that the depolarization and entry of Ca 2ϩ observed in the presence of forskolin, although smaller than those with 1 mM 4AP, are enough to maximally stimulate the release of glutamate. In contrast, forskolin failed to alter the fura-2 response (Fig. 5B ) and the plasma membrane depolarization (Fig. 5D) evoked by a submaximal concentration (10 mM) of KCl, which is consistent with the requirement of action potentials in order for the forskolin effect to be observed.
Presynaptic ␤-Adrenergic Receptor Enhances cAMP Levels and Activates PKA-dependent Facilitation of Glutamate
Release-The addition of glutamate, histamine, serotonin, and dopamine, all at 100 M, for 2 min failed to enhance intrasynaptosomal cAMP (Fig. 6) . By contrast, the ␤-adrenergic agonist isoproterenol enhanced cAMP production to values close to those obtained with 100 M forskolin (Fig. 6 ). This result is consistent with the presence of adrenergic innervation in the cortex (31) and with the ability of ␤-adrenergic agonists to increase cAMP levels in this region (32) . Dose-response curves for isoproterenol on cAMP production indicate an EC 50 value of 9.54 ϫ 10 Ϫ7 M (Fig. 7) . This isoproterenol effect was partially prevented or abolished by the ␤-adrenergic antagonist propanolol at 10 and 100 M, respectively (Fig. 7) . The depolarization of nerve terminals with 4AP did not alter the intrasynaptosomal levels of cAMP in the absence of agonist, but induced a shift to the left of the concentrationresponse curve, reducing the EC 50 value for isoproterenol to 4.26 ϫ 10 Ϫ8 M (Fig. 7) . Thus, the optimal activation of presynaptic adenylyl cyclase requires both the ␤-adrenergic agonist and an elevated concentration of Ca 2ϩ . Isoproterenol potentiated the release evoked by 50 M 4AP (Fig. 8A) , and this effect was completely prevented by the ␤-adrenergic antagonist propanolol, by the PKA inhibitor H89, and by the inactive cAMP analogue (R p )-8-Cl-cAMP-S (Fig. 8B) . It therefore seems that the presynaptic ␤-adrenergic receptor is coupled to the cAMP/PKA facilitatory pathway in cerebrocortical nerve terminals.
DISCUSSION
The results of this study demonstrate the presence of a cAMP/PKA-dependent facilitatory pathway in the nerve terminals from the cerebral cortex and that noradrenaline, acting through a ␤-adrenergic receptor, is the extracellular signal able to activate this pathway. Several lines of evidence support these conclusions. First, agents able to increase cAMP, such as forskolin, or those mimicking the effect of cAMP, such as the membrane permeant cAMP analogue dibutyryl cAMP, induce Ca 2ϩ -dependent glutamate release, whereas the inactive compound 1,9-dideoxyforskolin is without effect. Second, the forskolin-induced elevation of cAMP fails to evoke the release of glutamate in the presence of the protein kinase A inhibitors H89 and (R p )-8-Cl-cAMP-S. Third, the ␤-adrenergic receptor agonist isoproterenol increases cAMP levels and glutamate release, and both actions are antagonized by the receptor antagonist propanolol. Finally, isoproterenol facilitates glutamate release by a mechanism sensitive to the PKA inhibitors H89 and (R p )-8-Cl-cAMP-S.
The finding that forskolin increases cAMP levels in a Ca 2ϩ -dependent manner is consistent with the expression in the cortex of type I adenylyl cyclase activated by Ca 2ϩ and calmodulin (1). Although unstimulated Ca 2ϩ levels are sufficient to make it possible to observe the increased cAMP (Fig. 1A) and to induce the facilitation of release ( Fig. 2A) in the presence of forskolin, the shift to the left in the concentration-response curve for isoproterenol in cAMP production (Fig. 7) indicates a role for Ca 2ϩ in this pathway. Thus, presynaptic adenylyl cyclase may act as a coincidence detector, integrating glutama- tergic neurotransmission, through the increase in Ca 2ϩ provided by presynaptic activity, and noradrenaline release.
The depolarization of nerve terminals with either KCl or 4AP evokes a similar extent of Ca 2ϩ -dependent release that originates from the same glutamate pool (25) . However, a different set of presynaptic channels are activated in each case, as is indicated by the insensitivity of KCl-evoked release to the Na ϩ channel blocker TTX (25) . The clamped depolarization imposed by KCl prevents a significant contribution to the release process of those channels undergoing a rapid inactivation, like the Na ϩ or K ϩ channels. Although these channels can be initially active, the inactivate, remaining in this form for the rest of the stimulation period and thus making no significant contribution to the release process. In contrast, 4-aminopyridine, by inhibiting dendrotoxin-sensitive K ϩ channels (25) , initiates spontaneous action potentials blocked by TTX.
The differences between KCl-and 4AP-stimulated nerve terminals become more apparent when we study release modulation by mechanisms that rely on action potential intensity control, such as the protein kinase C-mediated facilitation of glutamate release observed in 4AP-but not KCl-stimulated nerve terminals (33) . In this case, protein kinase C inhibits a delayed rectifier K ϩ -type channel, resulting in enhanced action potentials and increased release (33) . The finding reported here that forskolin fails to enhance glutamate release under KCl depolarization, together with the observation that TTX inhibits the cAMP-induced facilitation, clearly indicates the involvement of action potentials in the facilitatory process. The involvement of an increase in nerve terminal excitability in the cAMP action is also supported by the ability of arachidonic acid to abolish this facilitatory effect. Arachidonic acid has been shown to inhibit Na ϩ channels (29) and to reduce synaptic transmission (27) through a decrease in glutamate release (28) . More difficult to establish is the channel type modulated by PKA, although inhibition of Ca 2ϩ -dependent K ϩ channels has been reported in pyramidal (34, 35) and granular (36) hippocampal neurons.
Presynaptic Ca 2ϩ channels have been reported to be phosphorylated by cAMP-dependent protein kinase in hippocampal neurons (37) . This finding, together with the recent report that isoproterenol potentiates synaptic transmission by enhancing presynaptic Ca 2ϩ influx via P/Q-type calcium channels in rat amygdala (11) , provides further evidence of a presynaptic facilitatory effect for the cAMP/PKA pathway. Vesicle mobilization may also be the consequence of a presynaptic PKA action since it has been demonstrated that phosphorylation of the vesicle-associated protein synapsin I by PKA enhances vesicle mobilization to the plasma membrane and transmitter release in the squid giant synapse (38) , in rat hippocampus (39) , and in cat neocortical neurons (40) . However, two pieces of evidence suggest that vesicle mobilization does not seem to be the main effect of PKA. First, the increase in spontaneous release by cAMP is likely to affect initially vesicles docked at the plasma membrane rather than distal vesicles, which would require mobilization before fusion can take place. In this regard, the analysis of the evoked release of glutamate into a fast and a slow component, which probably represent the release of docked and mobilized vesicles, respectively, has shown that forskolin induces a greater enhancement of the fast release component. 2 Another fact making it unlikely that vesicle mobilization is responsible for the facilitatory effect of cAMP is the previous observation that KCl and 4AP are equally effective in inducing the Ca 2ϩ -dependent vesicle mobilization (41, 42) , whereas in this work, no facilitation by forskolin was observed to occur in the presence of KCl. Thus, although vesicle mobilization may be involved in cAMP/PKA action, this might not be the primary effect of the pathway at the presynaptic level. More recently, it has been demonstrated that the synaptic vesicle protein rabphilin 3A is also a substrate for cAMP-dependent protein kinases in vitro (43) , although the effects of such phosphorylation on neurotransmitter release have not been established.
The presence in the cortex of a presynaptic ␤-adrenergic receptor linked to the cAMP pathway is consistent with the evidence that noradrenergic neurons of the locus ceruleus innervate the cerebral cortex (31) . Although the existence of other presynaptic receptors coupled to the cAMP pathway cannot be excluded, the finding that the ␤-adrenergic agonist isoproterenol increases cAMP to a similar extent as forskolin suggests that ␤-adrenergic receptor-sensitive nerve terminals overlap forskolin-sensitive nerve terminals. In addition, ago-2 I. Herrero and J. Sá nchez-Prieto, unpublished results. nists of other receptors known to be coupled to adenylyl cyclase stimulation failed to increase cAMP levels under conditions in which the potential occlusion of their effects by tonic activation of adenosine A 1 receptors coupled to adenylyl cyclase inhibition was limited by the presence of adenosine deaminase.
This paper provides evidence for the presence of a cAMP/ PKA pathway linked to ␤-adrenergic receptors facilitating glutamate release by increasing nerve terminal excitability. We have previously found that the population of cerebrocortical nerve terminals also exhibits a diacylglycerol/protein kinase C-dependent pathway that facilitates the release of glutamate (33) . In this case, a metabotropic glutamate receptor activates diacylglycerol production, resulting in an increase in the evoked action potential intensity and glutamate release (17) . Further research is now needed in order to study whether both facilitatory pathways coexist in individual nerve terminals; but if so, they would provide the molecular machinery to integrate the release of glutamate and noradrenaline into presynaptic potentiation at glutamatergic synapses.
